Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 154,712,800
  • Shares Outstanding, K 1,240,680
  • Annual Sales, $ 28,754 M
  • Annual Income, $ 480,000 K
  • EBIT $ 10,490 M
  • EBITDA $ 13,257 M
  • 60-Month Beta 0.32
  • Price/Sales 5.42
  • Price/Cash Flow 18.29
  • Price/Book 7.27

Options Overview Details

View History
  • Implied Volatility 25.01% (-1.02%)
  • Historical Volatility 20.96%
  • IV Percentile 23%
  • IV Rank 15.30%
  • IV High 49.97% on 04/08/25
  • IV Low 20.50% on 01/08/25
  • Expected Move (DTE 3) 1.79 (1.44%)
  • Put/Call Vol Ratio 0.87
  • Today's Volume 4,092
  • Volume Avg (30-Day) 14,384
  • Put/Call OI Ratio 0.77
  • Today's Open Interest 161,214
  • Open Int (30-Day) 172,073
  • Expected Range 123.12 to 126.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.86
  • Number of Estimates 6
  • High Estimate 1.96
  • Low Estimate 1.80
  • Prior Year 1.90
  • Growth Rate Est. (year over year) -2.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
118.17 +5.70%
on 12/16/25
127.41 -1.96%
on 12/23/25
-0.93 (-0.74%)
since 11/28/25
3-Month
108.46 +15.17%
on 10/02/25
128.70 -2.94%
on 11/20/25
+12.29 (+10.91%)
since 09/29/25
52-Week
88.57 +41.03%
on 01/10/25
128.70 -2.94%
on 11/20/25
+30.80 (+32.73%)
since 12/27/24

Most Recent Stories

More News
Gilead Sciences to Present at Upcoming Investor Conference

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January...

GILD : 124.91 (+0.17%)
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years –

ASMB : 33.32 (-0.89%)
GILD : 124.91 (+0.17%)
Trump announces lower drug price deals with 9 pharmaceutical companies

U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the U.S. Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead...

AZN.LN : 13,748.000 (+0.54%)
GILD : 124.91 (+0.17%)
AMGN : 329.63 (-0.99%)
PFE : 25.00 (-0.36%)
Why Gilead Sciences (GILD) Stock Is Up Today

Why Gilead Sciences (GILD) Stock Is Up Today

GILD : 124.91 (+0.17%)
Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans

Agreement addresses all requests by President Trump to reduce drug costs in the U.S., encourage global investment and protect American biopharma leadership ...

GILD : 124.91 (+0.17%)
Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company’s...

GILD : 124.91 (+0.17%)
3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains

GILD, AMAT, and QCOM all stand out for their capacity to generate cash flow, which allows them to increase value to shareholders through dividends and buybacks.

AMAT : 263.05 (+0.44%)
QCOM : 173.43 (-0.79%)
GILD : 124.91 (+0.17%)
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial

– Investigational Treatment Regimen Could Expand Options for Virologically Suppressed Adults – – Positive Phase 3 Results from...

GILD : 124.91 (+0.17%)
3 Profitable Stocks We Keep Off Our Radar

3 Profitable Stocks We Keep Off Our Radar

EPC : 17.38 (-0.57%)
GILD : 124.91 (+0.17%)
CHD : 85.34 (-0.06%)
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer

– Funding Empowers 53 Organizations to Enhance Education, Care and Support Services –

GILD : 124.91 (+0.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 126.46
2nd Resistance Point 125.86
1st Resistance Point 125.39
Last Price 124.91
1st Support Level 124.32
2nd Support Level 123.72
3rd Support Level 123.25

See More

52-Week High 128.70
Last Price 124.91
Fibonacci 61.8% 113.37
Fibonacci 50% 108.63
Fibonacci 38.2% 103.90
52-Week Low 88.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar